Login to Your Account

Advicenne seeking $41M in Euronext IPO for EU filing, U.S. pivotal trial

By Cormac Sheridan
Staff Writer

Thursday, November 2, 2017

DUBLIN – Advicenne SA set out its stall this week with plans to raise up to €35 million (US$41 million) in an IPO on the Euronext in Paris, in order to continue clinical development of its lead therapy, ADV-7103, and to initiate the commercial rollout of the product in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription